Literature DB >> 15473356

Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis.

Claudia Montagnoli1, Silvia Sandini, Angela Bacci, Luigina Romani, Roberto La Valle.   

Abstract

Enolase, a 46-kDa glycolytic enzyme, is an immunodominant antigen of the opportunistic pathogen Candida albicans. A recombinant 6 x His-tagged enolase was studied, in conjunction with interleukin-12 (IL-12), as an adjuvant for cytokine induction favouring protection in a murine model of haematogenous candidiasis. Mice immunized with enolase plus IL-12 showed increased antibody titres against enolase, as well as increased median survival time and decreased fungal burden in kidneys, in comparison to non-immunized or IL-12-treated mice. This increased survival was attributable to enolase-induced cell-mediated immunity as it also occurred in B-cell-deficient mice. Enolase immunization stimulated a predominant T-helper-1 (Th1) cytokine pattern in splenic cells and induced production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) by purified CD4+ T cells. However, despite the elevation of immunogenicity, recombinant enolase induced only a modest protection against disseminated candidiasis, suggesting a form of protection likely attributable to the induction of a Th1 cell-mediated immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15473356     DOI: 10.1080/13693780310001644653

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  23 in total

1.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

2.  Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality.

Authors:  Rafael Zaragoza; Javier Pemán; Guillermo Quindós; Jose R Iruretagoyena; María S Cuétara; Paula Ramírez; Maria D Gómez; Juan J Camarena; Angel Viudes; José Pontón
Journal:  Clin Vaccine Immunol       Date:  2009-08-12

3.  Production of Plasmodium vivax enolase in Escherichia coli and its protective properties.

Authors:  Chao Zhang; Yaping Gu; Jianxia Tang; Feng Lu; Yuanyuan Cao; Huayun Zhou; Guoding Zhu; Jun Cao; Qi Gao
Journal:  Hum Vaccin Immunother       Date:  2016-08-03       Impact factor: 3.452

4.  Fungal antigens expressed during invasive aspergillosis.

Authors:  Nicole Denikus; Foteini Orfaniotou; Gerald Wulf; Paul F Lehmann; Michel Monod; Utz Reichard
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum.

Authors:  Aida Pitarch; César Nombela; Concha Gil
Journal:  Mol Cell Proteomics       Date:  2010-09-21       Impact factor: 5.911

Review 6.  The impact of proteomics on the understanding of functions and biogenesis of fungal extracellular vesicles.

Authors:  Marcio L Rodrigues; Ernesto S Nakayasu; Igor C Almeida; Leonardo Nimrichter
Journal:  J Proteomics       Date:  2013-04-10       Impact factor: 4.044

7.  Healthy human T-Cell Responses to Aspergillus fumigatus antigens.

Authors:  Neelkamal Chaudhary; Janet F Staab; Kieren A Marr
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

Review 8.  The role of the IL-12 cytokine family in directing T-cell responses in oral candidosis.

Authors:  Xiao-Qing Wei; Helen Rogers; Michael A O Lewis; David W Williams
Journal:  Clin Dev Immunol       Date:  2010-10-24

9.  Protective properties and surface localization of Plasmodium falciparum enolase.

Authors:  Ipsita Pal-Bhowmick; Monika Mehta; Isabelle Coppens; Shobhona Sharma; Gotam K Jarori
Journal:  Infect Immun       Date:  2007-09-04       Impact factor: 3.441

10.  Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence.

Authors:  Hui-Ching Ko; Ting-Yin Hsiao; Chiung-Tong Chen; Yun-Liang Yang
Journal:  J Microbiol       Date:  2013-06-28       Impact factor: 3.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.